MDGL stock forecast, quote, news & analysis
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality... Show more
Madrigal Pharmaceuticals (MDGL) Stock Analysis: Rezdiffra Momentum and Pipeline Expansion Fuel MASH Leadership
Key Takeaways
- Madrigal Pharmaceuticals (MDGL) traded near $551 as of late July 2026, reflecting a roughly 7.5% gain over the prior 30 days — staying within a moderate range that highlights ongoing consolidation.
- Rezdiffra (resmetirom) generated $311.3 million in first-quarter 2026 net sales, marking 127% year-over-year growth and achieving blockbuster status on a trailing-12-month basis.
- The company secured three new U.S. patents for resmetirom in June and July 2026, reinforcing intellectual property protection extending to 2045.
- Madrigal's MASH-focused pipeline now exceeds 10 programs, including siRNA assets, an oral GLP-1 candidate (MGL-2086), and a Phase 2 DGAT-2 inhibitor (ervogastat).
- Q2 2026 earnings are scheduled for July 30, with analysts closely watching Rezdiffra prescription trends and updates on the MAESTRO-NASH-OUTCOMES trial in compensated cirrhosis.
Current Market Snapshot
Madrigal Pharmaceuticals traded near the $551 level in late July 2026, posting a modest advance from the $512.65 close recorded on June 26. The stock has moved within a relatively contained range over the past month, with daily closes oscillating between roughly $507 and $565. This period of consolidation follows a more volatile stretch earlier in the quarter, when shares dipped as low as $445 in early June before rebounding sharply. Broader biotech sentiment has been mixed, yet Madrigal continues to command attention as the only company with an FDA- and EU-approved therapy for MASH with moderate to advanced fibrosis — a market estimated to include millions of eligible patients in the U.S. alone. Institutional ownership remains exceptionally high at approximately 98.5%, underscoring deep conviction among large investors despite ongoing profitability debates.
Madrigal Pharmaceuticals (MDGL) Business Overview and Competitive Position
Madrigal Pharmaceuticals is a biopharmaceutical company singularly focused on metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease with significant unmet medical need. The company's flagship product, Rezdiffra (resmetirom), is a once-daily oral THR-β agonist that directly targets the liver to address key drivers of MASH. Rezdiffra remains the first and only therapy approved by both the FDA and the European Commission for noncirrhotic MASH with moderate to advanced fibrosis (F2–F3).
Madrigal's competitive moat is built on three pillars: a first-mover advantage in a rapidly expanding MASH market now estimated at approximately 460,000 diagnosed patients; a robust intellectual property estate with patent protection extending to 2045; and an expanding pipeline of next-generation assets that includes siRNA gene-silencing programs, an oral GLP-1 receptor agonist (MGL-2086), and a DGAT-2 inhibitor (ervogastat). The company is also conducting the pivotal MAESTRO-NASH-OUTCOMES trial evaluating Rezdiffra in compensated MASH cirrhosis (F4c), which could materially broaden the drug's addressable market if successful.
Recent Developments Driving MDGL
Several developments have shaped MDGL's narrative over the past month. On July 13, Madrigal announced that the USPTO granted three new resmetirom patents, including two covering F2/F3 MASH that will be listed in the FDA's Orange Book and one covering methods for treating compensated cirrhosis (F4c). These patents further entrench Rezdiffra's commercial exclusivity well into the 2040s.
On the analyst front, Citizens JMP raised its price target to $739 while maintaining an Outperform rating, and UBS initiated coverage with a Buy rating and a $669 target. Meanwhile, BAC maintained a Neutral stance with a $542 target. The broader analyst consensus remains firmly bullish, with a "Moderate Buy" rating and an average price target near $688, though some analysts — including Wolfe Research — have flagged valuation concerns even under optimistic Rezdiffra sales assumptions.
Madrigal also announced it will release Q2 2026 financial results on July 30, a pivotal catalyst. Additionally, EASL Congress data presented in late May highlighted Rezdiffra's ability to improve atherogenic lipid profiles and reduce markers of portal hypertension risk, further supporting its clinical differentiation. On the strategic front, the company's pipeline continues to advance, with the MGL-2086 Phase 1 trial expected to initiate in the second quarter.
Trending AI Robots
For traders seeking to navigate complex biotech stocks like Madrigal Pharmaceuticals with data-driven precision, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of automated trading bots that actively trade thousands of tickers across diverse strategies and timeframes, but only the top-performing and most relevant bots appear in this featured section. Each bot is designed with a distinct methodology — ranging from swing trading and trend following to breakout strategies — and is backed by transparent, real-time performance metrics. Whether you are monitoring MASH-focused biotech names or scanning broader healthcare opportunities, this resource provides a practical way to explore algorithmic trading tools. Visit the Trending AI Robots page to see which strategies are currently generating the strongest signals.
2026 Outlook and What Investors Should Watch
Looking ahead, the Q2 2026 earnings report on July 30 stands as the immediate catalyst. Investors will scrutinize Rezdiffra's net sales trajectory following the modest 3% sequential decline observed between Q4 2025 and Q1 2026, as well as the total number of patients on therapy. Guidance updates, particularly around the endocrinology field force expansion and direct-to-consumer marketing initiatives, will be closely parsed for signals about the pace of commercial execution.
Beyond earnings, the MAESTRO-NASH-OUTCOMES trial in compensated cirrhosis (F4c) remains a critical longer-term value driver, with results expected in 2027. Pipeline milestones — including the MGL-2086 Phase 1 readout and the ervogastat/resmetirom drug-drug interaction study — will shape perceptions of Madrigal's ability to build a next-generation combination therapy franchise. Macroeconomic risks, including potential drug pricing policy shifts and sector rotation within healthcare, also warrant attention. With approximately $818 million in cash and marketable securities as of March 31, 2026, Madrigal maintains a solid runway to execute its strategy, though the path from robust revenue growth to sustainable profitability remains the central question for investors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MDGL in upward trend: 10-day moving average moved above 50-day moving average on June 29, 2026
The 10-day moving average for MDGL crossed bullishly above the 50-day moving average on June 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MDGL's RSI Oscillator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where MDGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 168 cases where MDGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDGL as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MDGL turned negative on July 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
MDGL moved below its 50-day moving average on July 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.371) is normal, around the industry mean (20.076). P/E Ratio (0.000) is within average values for comparable stocks, (25.135). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.546). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (9.050) is also within normal values, averaging (412.299).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases
Industry Biotechnology